(Q46643620)

English

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor

scientific article published in April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

estrogen-receptor negative breast cancer

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shu-Chuan Weng

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Yoko Kashida

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Samuel K Kulp

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Dasheng Wang

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Robert W Brueggemeier

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Charles L Shapiro

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Ching-Shih Chen

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

publication date

1 April 2008

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

800-808

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Cell cycle and death control: long live Forkheads

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Mechanisms of tamoxifen-induced apoptosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-07-0434

Identifiers

10.1158/1535-7163.MCT-07-0434

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18413793

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46643620&oldid=2123734749"